EGFR and non-small cell lung carcinoma: Analysis of subgroups showed that in 1st-line treatment, atezolizumab combination therapy substantially enhanced OS compared to chemotherapy-based treatment in patients aged <65 years old; those aged 65–74 years old; male patients and female patients; patients with non-squamous NSCLC, PS 0, PS 1, and EGFR wild-type; those without liver metastasis; active or previous smokers; white patients; and those with TC1/2/3 or IC1/2/3, TC1/2 or IC1/2, and TC3 or IC3.